[1]秦子淋,曾健滢,牛立志.不可逆电穿孔消融治疗肝恶性肿瘤现状[J].介入放射学杂志,2017,(03):285-289.
 QIN Zilin,ZENG Jianying,NIU Lizhi.Irreversible electroporation ablation for the treatment of malignant tumors of liver: present clinical situation[J].journal interventional radiology,2017,(03):285-289.
点击复制

不可逆电穿孔消融治疗肝恶性肿瘤现状 ()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年03期
页码:
285-289
栏目:
综述
出版日期:
2017-03-25

文章信息/Info

Title:
Irreversible electroporation ablation for the treatment of malignant tumors of liver: present clinical situation
作者:
秦子淋 曾健滢 牛立志
Author(s):
QIN Zilin ZENG Jianying NIU Lizhi
Medical College, Ji’nan University, Guangzhou, Guangdong Province 510632, China
关键词:
【关键词】 不可逆电穿孔 肝癌 消融
文献标志码:
A
摘要:
【摘要】 肝恶性肿瘤发病率逐年增加。中国肝癌发病率为25.7/10万。然而,对侵犯或毗邻肝门重要脏器的肝恶性肿瘤,难以手术切除且化放疗疗效不佳。近年来,不可逆电穿孔(IRE)消融技术逐渐兴起,作为一种新的非热能形式的消融方法,其通过产生短时高压的电脉冲在细胞膜上产生纳米级的不可逆损伤。国内外研究指出,该技术在治疗不可手术切除的原发性或转移性肝肿瘤时,可有效灭活肿瘤组织并保留管腔架构,不会损伤大血管或胆管等。本文对IRE的设备构成、作用机制、临床前研究、临床应用方法以及临床疗效进行综述,以期为该技术在临床得以推广应用提供参考。

参考文献/References:

[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136: E359- E386.
[2] Cha C, Fong Y, Jarnagin WR, et al. Predictors and patterns of recurrence after resection of hepatocellular carcinoma[J]. J Am Coll Surg, 2003, 197: 753- 758.
[3] 吴孟超, 陈 汉, 沈 锋, 等. 微创在肝癌外科治疗中的地位[J]. 中国微创外科杂志, 2002, 2: 69- 70.
[4] Cucchetti A, Piscaglia F, Cescon M, et al. Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma[J]. World J Gastroenterol, 2013, 19: 4106- 4118.
[5] Itoh S, Ikeda Y, Kawanaka H, et al. Efficacy of surgical microwave therapy in patients with unresectable hepatocellular carcinoma[J]. Ann Surg Oncol, 2011, 18: 3650- 3656.
[6] Mu F, Niu L, Li H, et al. Percutaneous comprehensive cryoablation for metastatic hepatocellular cancer[J]. Cryobiology, 2013, 66: 76- 80.
[7] Jourabchi N, Beroukhim K, Tafti BA. Irreversible electroporation (NanoKnife) in cancer treatment[J]. Gastrointest Interv, 2014, 3: 8- 18.
[8] Ben- David E, Appelbaum L, Sosna J, et al. Characterization of irreversible electroporation ablation in in vivo porcine liver[J]. AJR Am J Roentgenol, 2012, 198: W62- W68.
[9] Au JT, Kingham TP, Jun K, et al. Irreversible electroporation ablation of the liver can be detected with ultrasound B- mode and elastography[J]. Surgery, 2013, 153: 787- 793.
[10] Sommer CM, Fritz S, Vollherbst D, et al. CT- guided irreversible electroporation in an acute porcine liver model: effect of previous transarterial iodized oil tissue marking on technical parameters, 3D computed tomographic rendering of the electro- poration zone, and histopathology[J]. Cardiovasc Intervent Radiol, 2015, 38: 191- 200.
[11] Schmidt CR, Shires P, Mootoo M. Real- time ultrasound imaging of irreversible electroporation in a porcine liver model adequately characterizes the zone of cellular necrosis[J]. HPB (Oxford), 2012, 14: 98- 102.
[12] Chung DJ, Sung K, Osuagwu FC, et al. Contrast enhancement patterns after irreversible electroporation: experimental study of CT perfusion correlated to histopathology in normal porcine liver[J]. J Vasc Interv Radiol, 2016, 27: 104- 111.
[13] Choi JW, Lu DS, Osuagwu F, et al. Assessment of chronological effects of irreversible electroporation on hilar bile ducts in a porcine model[J]. Cardiovasc Intervent Radiol, 2014, 37: 224- 230.
[14] Charpentier KP, Wolf F, Noble L, et al. Irreversible electroporation of the liver and liver hilum in swine[J]. HPB(Oxford), 2011, 13: 168- 173.
[15] Golberg A, Bruinsma BG, Jaramillo M, et al. Rat liver regeneration following ablation with irreversible electroporation[J]. Peer J, 2016, 4: e1571.
[16] 张 欣, 肖越勇, 杜 鹏, 等. 经皮纳米刀消融小型猪肝组织的安全性及有效性[J]. 中国介入影像与治疗学, 2015, 12: 259- 262.
[17] 梁 冰, 牛立志, 曾健滢, 等. 不可逆电穿孔消融兔胆囊侧肝脏病理学观察[J]. 介入放射学杂志, 2014, 23: 320- 324.
[18] 朱统寅, 孙军辉, 陈新华, 等. CT导引纳米刀消融猪肝脏可行性实验研究[J]. 介入放射学杂志, 2016, 25: 337- 340.
[19] Cheung W, Kavnoudias H, Roberts S, et al. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes[J]. Technol Cancer Res Treat, 2013, 12: 233- 241.
[20] Lencioni R, Crocetti L, Narayanan G. Irreversible electroporation in the treatment of hepatocellular carcinoma[J]. Tech Vasc Interv Radiol, 2015, 18: 135- 139.
[21] Verslype C, Rosmorduc O, Rougier P, et al. Hepatocellular carcinoma: ESMO- ESDO clinical practice guidelines for diagnosis, treatment and follow- up[J]. Ann Oncol, 2012, 23(Suppl 7): vii41- vii48.
[22] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53: 1020- 1022.
[23] Cannon R, Ellis S, Hayes D, et al. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures[J]. J Surg Oncol, 2013, 107: 544- 549.
[24] Froud T, Venkat SR, Barbery KJ, et al. Liver function tests following irreversible electroporation of liver tumors: experience in 174 procedures[J]. Tech Vasc Interv Radiol, 2015, 18: 140- 146.
[25] Eisele RM, Chopra SS, Glanemann M, et al. Risk of local failure after ultrasound guided irreversible electroporation of malignant liver tumors[J]. Interv Med Appl Sci, 2014, 6: 147- 153.
[26] Ball C, Thomson KR, Kavnoudias H. Irreversible electroporation: a new challenge in “out of operating theater” anesthesia[J]. Anesth Analg, 2010, 110: 1305- 1309.
[27] 郭秀琼, 杨国仁, 陈 涛, 等. 麻醉后恢复室病人常见并发症的原因分析及处理[J]. 西南军医, 2010, 12: 1064- 1066.
[28] Kingham TP, Karkar AM, D’angelica MI, et al. Ablation of perivascular hepatic malignant tumors with irreversible electro- poration[J]. J Am Coll Surg, 2012, 215: 379- 387.
[29] Goldberg SN, Grassi CJ, Cardella JF, et al. Image- guided tumor ablation: standardization of terminology and reporting criteria[J]. Radiology, 2005, 235: 728- 739.
[30] Ahmed M, Technology Assessment Committee of the Society of Interventional Radiology. Image- guided tumor ablation: standar- dization of terminology and reporting criteria: a 10- year update: supplement to the consensus document[J]. J Vasc Interv Radiol,2014, 25: 1706- 1708.
[31] Scheffer HJ, Nielsen K, De Jong MC, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy[J]. J Vasc Interv Radiol, 2014, 25: 997- 1011.
[32] 丁 婕, 戴 旭, 孟宪运, 等. 实体瘤疗效评价标准的研究进展[J]. 中国肿瘤临床与康复, 2015, 22: 1150- 1152.
[33] Eller A, Schmid A, Schmidt J, et al. Local control of perivascular malignant liver lesions using percutaneous irreversible electro- poration: initial experiences[J]. Cardiovasc Intervent Radiol, 2015, 38: 152- 159.
[34] Kos B, Voigt P, Miklavcic D, et al. Careful treatment planning enables safe ablation of liver tumors adjacent to major blood vessels by percutaneous irreversible electroporation(IRE)[J]. Radiol Oncol, 2015, 49: 234- 241.
[35] Kasivisvanathan V, Thapar A, Oskrochi Y, et al. Irreversible electroporation for focal ablation at the porta hepatis[J]. Cardiovasc Intervent Radiol, 2012, 35: 1531- 1534.
[36] Scheffer HJ, Nielsen K, van Tilborg AA, et al. Ablation of colorectal liver metastases by irreversible electroporation: results of the COLDFIRE-Ⅰablate- and- resect study[J]. Eur Radiol, 2014, 24: 2467- 2475.
[37] Hosein PJ, Echenique A, Loaiza- Bonilla A, et al. Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system[J]. J Vasc Interv Radiol, 2014, 25: 1233- 1239.
[38] Schoellhammer HF, Goldner B, Merchant SJ, et al. Colorectal liver metastases: making the unresectable resectable using irreversible electroporation for microscopic positive margins: a case report[J]. BMC Cancer, 2015, 15: 271.
[39] Golberg A, Yarmush ML. Nonthermal irreversible electroporation: fundamentals, applications, and challenges[J]. IEEE Trans Biomed Eng, 2013, 60: 707- 714.
[40] Bruix J, Izzo F, Crocetti L, et al. 1408 irreversible electroporation for treatment of early- stage hepatocellular carcinoma. A prospective multicenter phrase 2 study assessing safety and efficacy[J]. J Hepatol, 2012, 56(Suppl 2): s544.
[41] Lencioni R, Crocetti L. Local- regional treatment of hepatocellular carcinoma[J]. Radiology, 2012, 262: 43- 58.
[42] 孙 钢. 不可逆电穿孔技术消融肿瘤研究进展[J]. 介入放射学杂志, 2015, 24: 277- 281.

相似文献/References:

[1]王建新,许成平,邵亚男,等. 125Ⅰ-LUF体毛导向治疗晚期肝癌初步报告[J].介入放射学杂志,1997,(01):16.
[2]龚承友,初曙光,陈陵际,等.蓖麻蛋白对裸鼠肝癌瘤体内注射的疗效及骨髓抑制的研究[J].介入放射学杂志,1997,(04):219.
[3]马广勤,高从敬,万向荣,等.晚期肝癌变异性、寄生性供血的基础研究[J].介入放射学杂志,1998,(02):95.
[4]刘传方,詹迎江.外生型肝癌三例[J].介入放射学杂志,1998,(03):190.
[5]程红岩,曲增强,徐爱民,等.肝癌介入治疗中预防副反应的初步探讨[J].介入放射学杂志,1998,(03):161.
[6]黄小明,于淼,暴军玲,等.甲氧氯普胺治疗肝癌介入治疗中的胃肠道反应[J].介入放射学杂志,1998,(04):245.
[7]张桂敏,陆翠玉.肝癌介入治疗术后物品的消毒处理[J].介入放射学杂志,1998,(04):244.
[8]杨熙章,吴纪瑞,杨永岩,等.灌注化疗预防肝癌术后复发[J].介入放射学杂志,1999,(02):32.
[9]钟力,夏海平,王吉先,等.肝动脉栓塞化疗结合超声导向注射酒精治疗肝癌的疗效观察[J].介入放射学杂志,1992,(01):48.
[10]李章钧.晚期肝梅毒误为肝癌一例[J].介入放射学杂志,1993,(01):4.
[11]李 鑫,刘凤永,袁宏军,等.纳米刀治疗肝癌 [J].介入放射学杂志,2017,(10):939.
 LI Xin,LIU Fengyong,YUAN Hongjun,et al.Nano knife: a newly- developed technique for the treatment of liver cancers[J].journal interventional radiology,2017,(03):939.
[12]许 敏,许丹霞,蒋天安.不可逆电穿孔技术在肝癌消融治疗中的应用[J].介入放射学杂志,2022,31(05):511.
 XU Min,XU Danxia,JIANG Tianan..Application of irreversible electroporation in the ablation treatment of liver cancer[J].journal interventional radiology,2022,31(03):511.

备注/Memo

备注/Memo:
(收稿日期:2016-04-17)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2017-03-14